Information disclosure
24
2023
-
02
Announcement of Scientific and Technological Achievements Transformation [2023] No. 2
In accordance with the Law of the People's Republic of China on Promoting the Transformation of Scientific and Technological Achievements, the Administrative Measures for the Protection and Transformation of Intellectual Property Rights and Scientific and Technological Achievements of Shenzhen Bay Laboratory (for Trial Implementation), and the Administrative Measures for the Protection and Transformation of Intellectual Property Rights and Scientific and Technological Achievements of Pingshan Biomedical R&D and Transformation Center of Shenzhen Bay Laboratory (for Trial Implementation), after the application of the person who completed the achievements, the review of the Comprehensive Department (scientific research), and the deliberation of the Office of the Director of Pingshan Center, the transformation of patented technologies of Li Zigang, Yin Feng and other completers is hereby announced as follows:
Outcome Name: A peptide inhibitor for the treatment of triple-negative breast cancer and its preparation method and use
Conversion method: free license (jointly build a joint research institute, get 4.333359% of the company's equity)
Cooperation company: Shenzhen Huayao Kangming Biopharmaceutical Co., Ltd
Pricing method: The third-party institution negotiates the price after evaluation, and the valuation is ¥54,000.00 yuan.
Income distribution: Shenzhen Shenwan Transformation Investment Co., Ltd. obtained 80% of the income, accounting for 3.466657% of the shares; Shenzhen Shenwan Transformation Investment Partnership (Limited Partnership) received 20% of the income, accounting for 0.866702% of the shares.
Publicity period: February 2023, 2 to March 24, 2023, a total of 3 days.
Objection handling: If there is any objection to the above transformation matters, please reflect to the leaders of the comprehensive department or the center through letters, calls, visits, etc. during the publicity period (contact: Xiao Ran; Contact email: xiaoran@szbl.ac.cn). We will keep it strictly confidential and will not be accepted after the deadline.
Information table of proposed conversion/licensing results
|
serial number |
Patent name |
Type of patent |
Patent number |
Patentee |
Inventor |
application date |
|
1 |
Peptide inhibitor for the treatment of triple-negative breast cancer and preparation method and use thereof |
Invention patents |
202210987769.1 |
Shenzhen Bay Laboratory Pingshan Biomedical R&D and Transformation Center |
LI Zigang, YIN Feng, CHEN Hailing, ZHAN Meimiao, LIU Jianbo, KONG Lingwei |
2022/8/17 |
Shenzhen Bay Laboratory Pingshan Biomedical R&D and Transformation Center
February 2023, 2
Related Information
Notice on Holding a Safety Work Meeting
2022-06-13
E-mail: ptmc@szbl.ac.cn Address: 7-14/F, Block B, Building A, Building 3, High tech Industry University Research Base, No. 16 Lanjing Road, Kengzi Street, Pingshan District, Shenzhen, Guangdong Province Zip code: 518118
Copyright © 2022 Shenzhen Bay Laboratory Pingshan Biopharmaceutical R&D and Transformation Center | SEO
Powered by www.300.cn